Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
Tema Neuroscience and Mental Health ETF (MNTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: MNTL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 0.2% | Avg. Invested days 70 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Volume (30-day avg) - | Beta - | 52 Weeks Range 19.86 - 27.39 | Updated Date 06/30/2025 |
52 Weeks Range 19.86 - 27.39 | Updated Date 06/30/2025 |
Upturn AI SWOT
Tema Neuroscience and Mental Health ETF
ETF Overview
Overview
The Tema Neuroscience and Mental Health ETF (MENT) focuses on companies involved in neuroscience, mental health treatments, and related technologies, targeting growth in this evolving sector.
Reputation and Reliability
Tema ETFs is a relatively new issuer focused on thematic investing. Their reputation is still building.
Management Expertise
The management team has experience in thematic investing and healthcare, but their track record is still being established.
Investment Objective
Goal
To provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the Tema Neuroscience and Mental Health Index.
Investment Approach and Strategy
Strategy: The ETF aims to track the Tema Neuroscience and Mental Health Index, which selects companies involved in the neuroscience and mental health space.
Composition The ETF primarily holds stocks of companies involved in the neuroscience and mental health sectors, including pharmaceuticals, biotechnology, and technology companies.
Market Position
Market Share: Data not readily available due to specificity of the fund and the lack of publicly available information.
Total Net Assets (AUM): Data not readily available due to specificity of the fund and the lack of publicly available information.
Competitors
Key Competitors
- XLV
- IBB
- XBI
- ARKG
Competitive Landscape
The ETF industry is competitive, dominated by larger healthcare and biotechnology ETFs. MENT faces competition from broad healthcare ETFs and specialized biotech funds. Its competitive advantage hinges on its targeted focus on neuroscience and mental health. A disadvantage is its smaller size and AUM.
Financial Performance
Historical Performance: Historical performance data is limited due to the ETF's relatively recent inception.
Benchmark Comparison: A relevant benchmark comparison would be against a blended index of healthcare and biotech ETFs; data is limited due to the short trading history.
Expense Ratio: 0.75
Liquidity
Average Trading Volume
The ETF's liquidity can be assessed by its average trading volume, which may vary and influence order execution.
Bid-Ask Spread
The bid-ask spread impacts trading costs, and a narrower spread indicates better liquidity.
Market Dynamics
Market Environment Factors
Factors include advancements in neuroscience, increased awareness of mental health, regulatory changes, and economic conditions impacting healthcare spending.
Growth Trajectory
Growth trends depend on the adoption of new therapies, increased investment in mental health, and the performance of underlying holdings.
Moat and Competitive Advantages
Competitive Edge
MENT's advantage lies in its niche focus on neuroscience and mental health, capturing a growing interest in these areas. This targeted strategy could attract investors seeking exposure to specific companies and technologies. The fund's specialized approach differentiates it from broader healthcare ETFs. However, this narrow focus also introduces concentration risk.
Risk Analysis
Volatility
Volatility will depend on the underlying holdings, which may include growth stocks in the biotech and technology sectors.
Market Risk
Risks include regulatory hurdles, clinical trial failures, competition, and overall market sentiment towards healthcare and biotechnology sectors.
Investor Profile
Ideal Investor Profile
The ideal investor is someone interested in healthcare innovation, particularly in neuroscience and mental health, with a higher risk tolerance.
Market Risk
This ETF is more suitable for long-term investors willing to accept higher risk for potential growth in the neuroscience and mental health sectors.
Summary
MENT provides targeted exposure to the emerging field of neuroscience and mental health. It suits investors seeking growth in this specific area, who accept higher risk and understand the sector's dynamics. While its targeted approach is an advantage, the ETF carries concentration risk and has a limited trading history. The ETF's success relies on innovation and the market's appetite for mental health solutions, and may be more suitable for long-term, higher-risk portfolios.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Tema ETFs website
- ETF.com
- Morningstar
Disclaimers:
Investment involves risk, including the potential loss of principal. Past performance is not indicative of future results. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tema Neuroscience and Mental Health ETF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.